The short version
- Why people research itFat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
- What the evidence isFDA-approved on 1 April 2026 as Foundayo, for long-term weight management in adults with obesity, or overweight with at least one weight-related condition (Lilly, 1 Apr 2026).
- What to watchSevere belly pain with vomiting.
How Orforglipron works
First oral small-molecule (non-peptide) GLP-1 agonist — cAMP-biased partial agonist; food-independent absorption, no injection.
Every other GLP-1 drug in this catalog is a peptide. This one is not, and that single fact generates everything else on the page.
It is a partial agonist, and it is biased. The same work reports partial agonism at the GLP-1 receptor with signaling biased toward G protein activation over beta-arrestin recruitment Kawai 2020. Beta-arrestin is the arm that internalizes and desensitizes a receptor after it fires.
- Oral
Research on Orforglipron5 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Evidence on file: FDA-approved for obesity (Foundayo, Apr 2026).
Human clinical evidence
FDA-approved on 1 April 2026 as Foundayo, for long-term weight management in adults with obesity, or overweight with at least one weight-related condition (Lilly, 1 Apr 2026). Eli Lilly's oral, non-peptide GLP-1 agonist. The ACHIEVE and ATTAIN programs reported HbA1c reduction in type 2 diabetes and weight loss in the 11–12% range at 72 weeks in obesity.
Read the number in context: it is below injectable semaglutide and well below tirzepatide, and above oral semaglutide. The trade is convenience against magnitude, not a new efficacy ceiling.
Correlative data
Marketed in the US only since April 2026, so real-world use is months old. Consistent with the class.
How the mechanism reads
A small molecule, not a peptide — which is the whole story. Peptides are destroyed by digestion, which is why oral semaglutide needs an absorption enhancer and still achieves roughly 1% bioavailability with strict fasting requirements.
MechanisticA non-peptide agonist sidesteps all of that: no injection, no absorption enhancer, no food-timing restrictions, and manufacturing at chemical rather than biological cost. That last point is why this molecule matters for access even though its effect size is not class-leading.
Mechanistic
Sources
- Kawai T, et al. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. Proceedings of the National Academy of Sciences 2020 · PMID 33177239
- Morse BL, et al. Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants. Clinical Pharmacology in Drug Development 2025 · PMID 40888509
- Ma X, et al. Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist. Diabetes Therapy 2024 · PMID 38402332
- Horn DB, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. The Lancet 2025 · PMID 41275875
- Wharton S, et al. Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials. Diabetes, Obesity and Metabolism 2026 · PMID 42338042
- Shirley M. Orforglipron: First Approval. Drugs 2026 · PMID 42479349
Orforglipron safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Personal or family history of medullary thyroid cancer or MEN2: a GLP-1 receptor class warning.
- History of pancreatitis or severe gastroparesis: slowed gastric emptying and pancreatic stimulation.
- Type 1 diabetes or insulin or sulfonylurea use: glucose can drop further.
- Strong CYP3A4 inducers or inhibitors: the drug is cleared through CYP3A4, so levels shift.
- Pregnancy or trying to conceive: deliberate weight loss is not advised in pregnancy, and no human pregnancy data exist.
What’s expected
- Lower appetite and early fullness, via GLP-1 receptor cAMP signaling.
- Nausea, constipation or loose stools early on.
- Slight rise in resting pulse.
- No needle required, and absorption that does not depend on food.
Watch for
- Severe belly pain with vomiting.
- Right upper pain or yellow eyes.
- Vision change if you have diabetes.
- Little urine, dizziness and dry mouth from dehydration.
Labs that tell you it’s working
- HbA1c (Hemoglobin A1c)
- Lipase
- Comprehensive Metabolic Panel (CMP)
- Cystatin C with eGFR
Orforglipron is an oral, non-peptide, cAMP-biased GLP-1 agonist cleared via CYP3A4; GLP-1 class effects apply without a glucagon arm. PMID 41275875 PMID 42338042
Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
The “On a GLP-1 (Semaglutide / Tirzepatide)” panel, explained
Orforglipron FAQ4 common questions
- Is Orforglipron approved for human use?
- Orforglipron is an approved medicine for the uses on its label. This page covers research beyond those uses, as education, not medical advice.
- What is Orforglipron researched for?
- Fat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
- Which labs show whether it's doing anything?
- HbA1c; Lipase; Comprehensive Metabolic Panel; Cystatin C with eGFR: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for Orforglipron: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.




